Skip to content

Florbetapir (18f)

Amyvid (florbetapir f 18) is a small molecule pharmaceutical. Florbetapir f 18 was first approved as Amyvid on 2012-04-06. It has been approved in Europe to treat radionuclide imaging. The pharmaceutical is active against amyloid-beta precursor protein. Amyvid's patent is valid until 2027-04-30 (FDA).
Trade Name Amyvid
Common Name Florbetapir (18f)
Indication radionuclide imaging
Drug Class
Florbetapir (18f)
Get full access now